Agios Pharmaceuticals (AGIO) Long-Term Investments (2013 - 2026)

Agios Pharmaceuticals' Long-Term Investments history runs 14 years deep, the most recent figure standing at $308.5 million for Q1 2026.

• Quarterly Long-Term Investments fell 41.94% year-over-year to $308.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $308.5 million (down 41.94% YoY) and the FY2025 annual result came in at $310.0 million, down 51.43% from the prior year.
• Long-Term Investments was $308.5 million for Q1 2026 at Agios Pharmaceuticals, down from $310.0 million in the prior quarter.
• Across five years, Long-Term Investments topped out at $655.9 million in Q3 2024 and bottomed at $29.4 million in Q4 2023.
• A 5-year average of $309.4 million and a median of $298.4 million in 2022 frame the typical range for Long-Term Investments.
• Annual changes were most pronounced in 2023 — Long-Term Investments sank 90.62% — and 2024, when it soared 2068.58%.
• Agios Pharmaceuticals' Long-Term Investments stood at $313.9 million in 2022, then sank by 90.62% to $29.4 million in 2023, then surged by 2068.58% to $638.3 million in 2024, then sank by 51.43% to $310.0 million in 2025, then retreated by 0.5% to $308.5 million in 2026.
• Business Quant data shows AGIO's Long-Term Investments at $308.5 million in Q1 2026, $310.0 million in Q4 2025, and $304.3 million in Q3 2025.